Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial

针对精神病临床高风险个体的以家庭为中心的治疗:一项验证性疗效试验

基本信息

  • 批准号:
    10256074
  • 负责人:
  • 金额:
    $ 170.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-07 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

Project Summary This proposal responds to RFA-MH-18-707, “Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01).” Adolescents and young adults at clinical high risk (CHR) for psychosis, characterized by recent onset or worsening of attenuated positive symptoms (APS), have a 16%-30% risk of converting to a psychotic disorder in 2 years. In a prior randomized trial in the North American Prodrome Longitudinal Study (NAPLS) network, we showed that family-focused therapy for clinical high-risk persons (FFT- CHR) was more effective than brief family education in (a) improving family (offspring/parent) communication and (b) reducing APS over 6 months, particularly among CHR youth with high baseline scores on a measure of individual risk of psychosis conversion. Both treatments were associated with reductions in young people's perceptions of criticism from parents, which in turn were associated with decreases in APS over 12 months. These findings led us to hypothesize enhanced family communication as a mechanism of action of FFT-CHR. FFT-CHR consists of 18 sessions in 6 months of psychoeducation, communication training, and problem-solving skills training. In the present study conducted in 7 NAPLS sites, we will randomly assign 220 CHR individuals (ages 13-25) and their parent(s) to FFT-CHR or a 6-month Enhanced Care (EC) treatment, consisting of 3 family educational sessions followed by 5 months of individual support and case management. CHR individuals will be interviewed and fill out questionnaires regarding APS (primary outcome) and social functioning (secondary) every 6 months over 18 months. We will examine behavioral targets indicative of improved family relationships: reductions in proportion of critical-conflictual statements and increases in proportion of calm-constructive statements of parents and CHR offspring in laboratory family interactional assessments conducted at baseline and end of treatment (6 months). We will also capture granular changes in targets and outcomes through remote monitoring: CHR participants in both conditions will enroll in a newly developed mobile phone app to facilitate weekly proband ratings of perceived criticism, appraisals of family interactions, and primary and secondary outcomes. We hypothesize that (1) youth/young adults in FFT-CHR will show greater improvements in APS than those in EC in 6 months; (2) improvements in parent and offspring communication by 6 months will be associated with downstream improvements in APS and social functioning over 18 months; and improvements in parent and offspring communication by 6 months will mediate the relationship between treatment condition and changes in primary and secondary outcomes over 18 months. We hypothesize that individuals who are at higher baseline risk of psychosis conversion will show more improvement in targets and primary and secondary outcomes in FFT-CHR than EC, compared to those at lower conversion risk. The involvement of 7 collaborative NAPLS sites with complementary expertise will assure accelerated recruitment of the sample, diagnostic reliability, sample diversity, and treatment exportability.
项目摘要 本提案响应RFA-MH-18-707,“非药理学药物的抗炎疗效临床试验” 精神疾病的干预措施(R 01)。处于精神病临床高风险(HAD)的青少年和年轻人, 特征为近期发作或减弱的阳性症状(APS)恶化,有16%-30%的风险 在两年内转变成精神病在之前的一项随机试验中, 纵向研究(NAPLS)网络,我们表明,以家庭为中心的治疗临床高危人群(FFT- 在(a)改善家庭(子女/父母)沟通方面, 和(B)在6个月内减少APS,特别是在基线得分高的青少年中, 精神病转化的个体风险。这两种治疗方法都与年轻人的 对父母批评的看法,这反过来又与12个月内APS的下降有关。 这些研究结果使我们假设增强家庭沟通作为一种机制的FFT-ESTA的行动。 FFT-BACK包括6个月的心理教育,沟通培训和解决问题的18个课程 技能培训。在7个NAPLS站点进行的本研究中,我们将随机分配220名受试者, (ages 13-25岁)及其父母接受FFT-CHR或6个月的加强护理(EC)治疗,由3个家庭组成 教育课程,然后是5个月的个人支持和个案管理。个人将被 访谈并填写有关APS(主要结局)和社会功能(次要结局)的问卷 每6个月超过18个月。我们将检查表明家庭关系改善的行为目标: 减少批评性-冲突性陈述的比例,增加冷静-建设性陈述的比例 基线时进行的实验室家庭干预评估中父母和子女的陈述 治疗结束(6个月)。我们还将通过远程监控, 监测:两种情况下的受试者都将注册一个新开发的移动的手机应用程序, 每周先证者对感知到的批评、对家庭互动的评价以及主要和次要的 结果。我们假设(1)FFT-OCT中的青年/年轻成人在APS方面的改善大于 6个月时父母和子女沟通的改善将与 18个月内APS和社会功能的下游改善;以及父母和 6个月的后代交流将介导治疗条件与 18个月内的主要和次要结局。我们假设那些处于较高基线的个体 精神病转换的风险将在目标和主要和次要结局方面显示出更多的改善, 与转换风险较低的人相比,FFT-BMPs高于EC。7个NAPLS协作站点的参与 与互补的专业知识将确保加速招募的样本,诊断的可靠性,样本 多样性和治疗出口。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CARRIE E BEARDEN其他文献

CARRIE E BEARDEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CARRIE E BEARDEN', 18)}}的其他基金

Understanding Rare Genetic Variation and Disease Risk: A Global Neurogenetics Initiative
了解罕见的遗传变异和疾病风险:全球神经遗传学倡议
  • 批准号:
    10660098
  • 财政年份:
    2023
  • 资助金额:
    $ 170.5万
  • 项目类别:
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
针对精神病临床高风险个体的以家庭为中心的治疗:一项验证性疗效试验
  • 批准号:
    10456871
  • 财政年份:
    2020
  • 资助金额:
    $ 170.5万
  • 项目类别:
ProNET: Psychosis-Risk Outcomes Network
ProNET:精神病风险结果网络
  • 批准号:
    10093852
  • 财政年份:
    2020
  • 资助金额:
    $ 170.5万
  • 项目类别:
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
针对精神病临床高风险个体的以家庭为中心的治疗:一项验证性疗效试验
  • 批准号:
    10041429
  • 财政年份:
    2020
  • 资助金额:
    $ 170.5万
  • 项目类别:
ProNET: Psychosis-Risk Outcomes Network
ProNET:精神病风险结果网络
  • 批准号:
    10440486
  • 财政年份:
    2020
  • 资助金额:
    $ 170.5万
  • 项目类别:
ProNET: Psychosis-Risk Outcomes Network
ProNET:精神病风险结果网络
  • 批准号:
    10464673
  • 财政年份:
    2020
  • 资助金额:
    $ 170.5万
  • 项目类别:
ProNET: Psychosis-Risk Outcomes Network
ProNET:精神病风险结果网络
  • 批准号:
    10625429
  • 财政年份:
    2020
  • 资助金额:
    $ 170.5万
  • 项目类别:
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
针对精神病临床高风险个体的以家庭为中心的治疗:一项验证性疗效试验
  • 批准号:
    10674012
  • 财政年份:
    2020
  • 资助金额:
    $ 170.5万
  • 项目类别:
ProNET: Psychosis-Risk Outcomes Network
ProNET:精神病风险结果网络
  • 批准号:
    10256743
  • 财政年份:
    2020
  • 资助金额:
    $ 170.5万
  • 项目类别:
3/9 Dissecting the effects of genomic variants on neurobehavioral dimensions in CNVs enriched for neuropsychiatric disorders
3/9 剖析基因组变异对富含神经精神疾病的 CNV 中神经行为维度的影响
  • 批准号:
    10083537
  • 财政年份:
    2019
  • 资助金额:
    $ 170.5万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 170.5万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 170.5万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 170.5万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 170.5万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 170.5万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 170.5万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 170.5万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 170.5万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 170.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 170.5万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了